BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28154994)

  • 1. Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer.
    Käsmann L; Bolm L; Schild SE; Janssen S; Rades D
    Lung; 2017 Apr; 195(2):217-224. PubMed ID: 28154994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?
    Sert F; Cosgun G; Yalman D; Ozkok S
    Cancer Radiother; 2021 Jun; 25(4):316-322. PubMed ID: 33422415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    Liu D; Huang Y; Li L; Song J; Zhang L; Li W
    BMC Cancer; 2017 Dec; 17(1):882. PubMed ID: 29268698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-lymphocyte ratio can predict outcome in extensive-stage small cell lung cancer.
    Drpa G; Sutic M; Baranasic J; Jakopovic M; Samarzija M; Kukulj S; Knezevic J
    Radiol Oncol; 2020 Sep; 54(4):437-446. PubMed ID: 32960780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers.
    Xie D; Marks R; Zhang M; Jiang G; Jatoi A; Garces YI; Mansfield A; Molina J; Yang P
    J Thorac Oncol; 2015 Aug; 10(8):1213-20. PubMed ID: 26200277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
    Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
    Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer.
    Sakin A; Sahin S; Yasar N; Demir C; Arici S; Geredeli C; Cihan S
    Oncol Res Treat; 2019; 42(10):506-515. PubMed ID: 31336378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.
    Suzuki R; Wei X; Allen PK; Cox JD; Komaki R; Lin SH
    Clin Lung Cancer; 2019 Mar; 20(2):117-123. PubMed ID: 30611672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer.
    Suzuki R; Lin SH; Wei X; Allen PK; Welsh JW; Byers LA; Komaki R
    Radiother Oncol; 2018 Mar; 126(3):499-505. PubMed ID: 29398150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
    Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM
    Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.
    Zhang Y; Jiang C; Li J; Sun J; Qu X
    Clin Transl Oncol; 2015 Oct; 17(10):810-8. PubMed ID: 26077119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer.
    Zhang H; Xia H; Zhang L; Zhang B; Yue D; Wang C
    Am J Surg; 2015 Sep; 210(3):526-35. PubMed ID: 26105800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
    Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
    J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer.
    Sun X; Liu X; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z
    Chin J Cancer; 2016 Jun; 35(1):57. PubMed ID: 27342313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.
    Kutlu Y; Aydin SG; Bilici A; Oven BB; Olmez OF; Acikgoz O; Hamdard J
    Medicine (Baltimore); 2023 Apr; 102(15):e33432. PubMed ID: 37058061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.